Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Reneo Pharmaceuticals, Inc. (RPHM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Investor presentation |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 9,081 $ 19,927 Short-term investments 133,596 81,246 Prepaid expenses and other current assets 3,643 5,180 Total current assets 146,320 106,353 Property and equipment, net 554 453 Right-of-use assets 1,086 1,292 Other non-current assets 79 84 Total assets $ 148,039 $ 108,182 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,828 $ 1,893 Accrued expenses 11,592 4,827 Operating lease liabilities, current portion 318 404 Total current liabilities 13,738 7,124 Operating lease liabilities, less current portion 897 1,059 Performance award 876 29 Total liabilities 15,511 8,212 Commitments and contingencies Stockholders’ equity: Comm..." |
|
| 07/27/2023 |
4
| GREY MICHAEL G (Executive Chairman) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Gifted 50,000 shares
@ $0 |
|
| 06/08/2023 |
4
| Mathers Edward T (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $9.01, valued at
$157.7k
|
|
| 06/08/2023 |
4
| Blunt Roshawn A. (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 14,815 options to buy
@ $9.01, valued at
$133.5k
|
|
| 06/08/2023 |
4
| GREY MICHAEL G (Executive Chairman) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $9.01, valued at
$157.7k
|
|
| 06/08/2023 |
4
| Hoelscher Paul W. (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $9.01, valued at
$157.7k
|
|
| 06/08/2023 |
4
| Muralidhar Bali (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $9.01, valued at
$157.7k
|
|
| 06/08/2023 |
4
| O'Donnell Niall (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $9.01, valued at
$157.7k
|
|
| 06/08/2023 |
4
| Seltzer Stacey Denenberg (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $9.01, valued at
$157.7k
|
|
| 06/08/2023 |
4
| Dube Eric M (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $9.01, valued at
$157.7k
|
|
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/30/2023 |
SC 13D/A
| RiverVest Venture Fund III, L.P. reports a 7.5% stake in RENEO PHARMACEUTICALS, INC. |
| 05/15/2023 |
SC 13D/A
| Novo Holdings A/S reports a 10.2% stake in Reneo Pharmaceuticals, Inc. |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
4
| O'Donnell Niall (Director) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Bought 125,000 shares
@ $8, valued at
$1M
|
|
| 05/09/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8.2% stake in Reneo Pharmaceuticals, Inc. |
| 05/05/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/27/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/27/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 19,927 $ 124,660 Short-term investments 81,246 23,010 Prepaid expenses and other current assets 5,180 6,064 Total current assets 106,353 153,734 Property and equipment, net 453 212 Right-of-use assets 1,292 — Other non-current assets 84 78 Total assets $ 108,182 $ 154,024 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,893 $ 2,022 Accrued expenses 4,827 4,180 Operating lease liabilities, current portion 404 — Total current liabilities 7,124 6,202 Operating lease liabilities, less current portion 1,059 — Other long-term liabilities — 167 Performance award 29 444 Total liabilities 8,212 6,813 Commitments and contingencies Stockholder..." |
|
| 03/14/2023 |
8-K
| Other Events Interactive Data |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 01/09/2023 |
8-K
| Investor presentation |
| 12/13/2022 |
4
| Lam Jennifer (VP of Finance & Administration) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 90,000 options to buy
@ $1.8, valued at
$162k
|
|
| 12/13/2022 |
4
| Hall Ashley (Chief Development Officer) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 125,000 options to buy
@ $1.8, valued at
$225k
|
|
| 12/13/2022 |
4
| FLESHER GREGORY J. (President and CEO) has filed a Form 4 on Reneo Pharmaceuticals, Inc.|
Txns:
| Granted 300,000 options to buy
@ $1.8, valued at
$540k
|
|
|
|
|